Abstract
Background. Prostate cancer (PC) ranks first in the structure of oncological pathology in men, being the second leading cause of cancer death and having 30 % as the five-year survival rate. Radiation therapy (RT) for prostate cancer has great potential for enhancement.
 Purpose – to evaluate the efficacy of RT in patients with prostate cancer and highlight the clinical and laboratory factors determining it.
 Materials and methods. The study enrolled 195 men with prostate cancer aged 52 to 82 years. The duration from the moment of diagnosis of the disease averaged 3 years. The Gleason score parameters were 6 points on average, the ratio of peripheral to central tumor form was 3:1, adenocarcinoma was diagnosed in 94 % of cases, giant cell carcinoma – in 6 %.
 Results. On average, recurring neoplasm is observed in 40 % of the patients with prostate cancer 2.5 years after radical prostatectomy combined with different methods of radiation therapy, which is associated with the initial indicators of the Gleason score, shape, localization and expansion of the tumor process, the presence of comorbid papillary carcinoma of the urinary bladder, metastases in the lymph nodes, distant viscera and the skeleton, while the power and direction of radiation exposure influence such radiotherapy complications as dermatitis, polyneuropathy, acute vascular insufficiency and tubulointerstitial nephritis.
 Conclusions. Developing the medical technology for RT in patients with prostate cancer to reduce the effect of prognostically unfavorable treatment factors is essential.
Highlights
Prostate cancer (PC) ranks first [1, 2] in the structure of oncological pathology in men, being, at the same time, the second leading cause of cancer death [3, 4]
I., prostate cancer to reduce the effect of prognostically unfavorable treat
We revealed that low survival of PC patients without simultaneous HT was observed when IWT (t = 4.10, p < 0.001) was increased by 85 % along with more frequent lymph node metastasizing (χ2 = 6.95, p = 0.008)
Summary
Prostate cancer (PC) ranks first [1, 2] in the structure of oncological pathology in men, being, at the same time, the second leading cause of cancer death [3, 4]. Purpose – to evaluate the efficacy of RT in patients на РПЗ і виокремити клініко-лабораторні фактори, with prostate cancer and highlight the clinical and laboraщо її визначають. Під спостереженням перебували 195 чоловіків із РПЗ віком від 52 до 82 років (у середньому (66,3 ± 6,89) років). Співвідношення периферичної та центральної форми РПЗ склало 3:1, локалізацію пухлини в задньому відділі простати встановлено в 56,9 % випадків, у бічних – в 36,9 %, у передньому – в 6,2 %. Аденокарциному діагностовано у 93,9 % від кількості обстежених хворих, гігантоклітинну карциному – у 6,2 %. Коморбідні додаткові пухлини в обстежених хворих на РПЗ були такими: папілярна карцинома сечового міхура мала місце в 3,1 % спостережень, світлоклітинна карцинома нирки – у 2,6 %, аденокарцинома грудної залози – у 1,0 %, плоскоклітинний рак шкіри – у 0,5 %
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
